Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study

• Published in: BMC psychiatry 2023-11, Vol.23 (1), p.830-830, Article 830
• Main Authors: Akter, Mst Sarmin, Emon, Faisal Abdullah, Nahar, Zabun, Shalahuddin Qusar, Mma, Islam, Sardar Mohammad Ashraful, Shahriar, Mohammad, Bhuiyan, Mohiuddin Ahmed, Islam, Md Rabiul
• Format: Article
• Language: English
• Subjects: Bangladesh; Blood-brain barrier; Brain; Case-Control Studies; Case-control study; Cerebrospinal fluid; Cytokines; Depressive Disorder, Major - psychology; Disease; Dopamine; Emotional disorders; Enzyme-linked immunosorbent assay; Enzymes; Humans; Interleukin 3; Interleukins; Lipocalin; Lipocalin-2; Major depressive disorder; Medical research; Medicine, Experimental; Mental depression; Mental disorders; Mental illness; Mood disorders; Neurological disorders; Pathogenesis; Pathophysiology; Psychiatry; Public health; Risk assessment; Serum levels; Sociodemographics; Somatotropin; Tumor necrosis factor-TNF
• ISSN: 1471-244X; 1471-244X
• DOI: 10.1186/s12888-023-05354-y

Major Depressive Disorder (MDD) is a common mental ailment and is the primary reason for disability. It manifests a severe impact on moods, thoughts, and physical health. At present, this disorder has become a concern in the field of public health. Alteration of neurochemicals is thought to be involved in the pathogenesis of many psychiatric disorders. Therefore, we aimed to evaluate serum IL-3 and lipocalin-2 in MDD patients and healthy controls (HCs). We included a total of 376 participants in this study. Among them, 196 were MDD patients, and 180 were age-sex-matched HCs. MDD patients were recruited from the Psychiatry Department of Bangabandhu Sheikh Mujib Medical University (BSMMU), but the controls were from different parts of Dhaka. All study participants were evaluated by a psychiatrist using the DSM-5 criteria. To assess the severity of the depression, we used the Hamilton depression (Ham-D) rating scale. Serum IL-3 and lipocalin-2 levels were measured using commercially available enzyme-linked immune-sorbent assay kits (ELISA kits). According to this study, we observed elevated serum levels of IL-3 (1,024.73 ± 29.84 pg/mL) and reduced levels of serum lipocalin-2 (29.019 ± 2.073 ng/mL) in MDD patients compared to HCs (911.11 ± 20.55 pg/mL and 48.065 ± 3.583 ng/mL, respectively). No associations between serum levels of IL-3 and lipocalin-2 and depression severity were observed in patients. According to the present findings, alterations of serum IL-3 and lipocalin might be associated with the pathogenesis of MDD. These results support that altered serum neurochemicals can serve as early risk assessment markers for depression. Further interventional studies are recommended for a better understanding of the role of IL-3 and lipocalin-2 in the pathophysiology of depression.